Experts at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) are involved in two investigational approaches with radioactive seeds that promise to improve the cure rates in men with prostate cancer.
One of these involves Taxotere chemotherapy with prostate brachytherapy to improve the chance for tumor control in men with aggressive cancers who are at high risk for recurrence. Taxotere is a new drug that is used in prostate cancer when it has spread to other parts of the body. Reports suggest that it has very high response rates in prostate cancer and that it has the ability to enhance the effects of the radiation.
The second study involves use of a new radioisotope (Cesium-131) for a boost to the prostate gland after image-guided pelvic Intensity Modulated Radiotherapy (IMRT), adjuvant chemotherapy and hormone therapy in patients with high risk prostate cancer.
For more information on our research studies for prostate cancer patients, see Clinical Trials.